Is Day One Stock a Good Investment?
Day One Investment Advice | DAWN |
- Examine Day One's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Day One's leadership team and their track record. Good management can help Day One navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Day One's business and its evolving consumer preferences.
- Compare Day One's performance and market position to its competitors. Analyze how Day One is positioned in terms of product offerings, innovation, and market share.
- Check if Day One pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Day One's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Day One Biopharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Day One Biopharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Day One Stock
Researching Day One's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by company insiders. The book value of Day One was currently reported as 5.51. The company recorded a loss per share of 0.97. Day One Biopharmaceu had not issued any dividends in recent years.
To determine if Day One is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Day One's research are outlined below:
| Day One Biopharmaceu generated a negative expected return over the last 90 days | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (188.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (146.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research ... |
Day One uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Day One Biopharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Day One's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Day One's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Day One's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-08 | 2021-09-30 | -0.28 | -0.33 | -0.05 | 17 | ||
2024-02-26 | 2023-12-31 | -0.58 | -0.64 | -0.06 | 10 | ||
2023-11-06 | 2023-09-30 | -0.6 | -0.54 | 0.06 | 10 | ||
2022-05-12 | 2022-03-31 | -0.38 | -0.48 | -0.1 | 26 | ||
2022-08-04 | 2022-06-30 | -0.49 | -0.6 | -0.11 | 22 | ||
2024-10-31 | 2024-09-30 | -0.2545 | 0.38 | 0.6345 | 249 | ||
2024-07-30 | 2024-06-30 | -0.75 | -0.05 | 0.7 | 93 | ||
2021-08-10 | 2021-06-30 | -0.31 | -5.04 | -4.73 | 1525 |
Know Day One's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Day One is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Day One Biopharmaceuticals backward and forwards among themselves. Day One's institutional investor refers to the entity that pools money to purchase Day One's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.9 M | Hhg Plc | 2024-06-30 | 1.8 M | Timessquare Capital Management, Llc | 2024-09-30 | 1.8 M | Geode Capital Management, Llc | 2024-06-30 | 1.3 M | Vestal Point Capital Lp | 2024-06-30 | 1.2 M | Maverick Capital Ltd | 2024-06-30 | 1.2 M | Boxer Capital Llc | 2024-09-30 | 1.2 M | First Turn Management Llc | 2024-09-30 | 947.9 K | Ra Capital Management, Llc | 2024-06-30 | 7.9 M | Fmr Inc | 2024-09-30 | 7.4 M |
Day One's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.37 B.Market Cap |
|
Day One's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.50) | (0.53) | |
| Return On Equity | (0.55) | (0.52) |
Determining Day One's profitability involves analyzing its financial statements and using various financial metrics to determine if Day One is a good buy. For example, gross profit margin measures Day One's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Day One's profitability and make more informed investment decisions.
Evaluate Day One's management efficiency
Day One Biopharmaceu has return on total asset (ROA) of (0.2543) % which means that it has lost $0.2543 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1784) %, meaning that it created substantial loss on money invested by shareholders. Day One's management efficiency ratios could be used to measure how well Day One manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.62. At this time, Day One's Net Tangible Assets are very stable compared to the past year. As of the 21st of November 2024, Non Currrent Assets Other is likely to grow to about 263.7 K, while Total Assets are likely to drop about 239.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.34 | 4.56 | |
| Tangible Book Value Per Share | 4.34 | 4.56 | |
| Enterprise Value Over EBITDA | (4.53) | (4.76) | |
| Price Book Value Ratio | 3.36 | 3.53 | |
| Enterprise Value Multiple | (4.53) | (4.76) | |
| Price Fair Value | 3.36 | 3.53 | |
| Enterprise Value | 934.3 M | 1.3 B |
Effective management at Day One has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Beta (1.52) |
Basic technical analysis of Day Stock
As of the 21st of November, Day One shows the Mean Deviation of 2.11, downside deviation of 2.88, and Coefficient Of Variation of 3283291.54. Day One Biopharmaceu technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Day One's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Day One insiders, such as employees or executives, is commonly permitted as long as it does not rely on Day One's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Day One insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Day One's Outstanding Corporate Bonds
Day One issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Day One Biopharmaceu uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Day bonds can be classified according to their maturity, which is the date when Day One Biopharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Day One's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Day One's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0071 | |||
| Market Risk Adjusted Performance | (0.000052) | |||
| Mean Deviation | 2.11 | |||
| Semi Deviation | 2.79 | |||
| Downside Deviation | 2.88 | |||
| Coefficient Of Variation | 3283291.54 | |||
| Standard Deviation | 2.54 | |||
| Variance | 6.45 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 11.44 | |||
| Value At Risk | (3.69) | |||
| Potential Upside | 3.84 | |||
| Downside Variance | 8.32 | |||
| Semi Variance | 7.76 | |||
| Expected Short fall | (1.99) | |||
| Skewness | (0.36) | |||
| Kurtosis | (0.44) |
| Risk Adjusted Performance | 0.0071 | |||
| Market Risk Adjusted Performance | (0.000052) | |||
| Mean Deviation | 2.11 | |||
| Semi Deviation | 2.79 | |||
| Downside Deviation | 2.88 | |||
| Coefficient Of Variation | 3283291.54 | |||
| Standard Deviation | 2.54 | |||
| Variance | 6.45 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 11.44 | |||
| Value At Risk | (3.69) | |||
| Potential Upside | 3.84 | |||
| Downside Variance | 8.32 | |||
| Semi Variance | 7.76 | |||
| Expected Short fall | (1.99) | |||
| Skewness | (0.36) | |||
| Kurtosis | (0.44) |
Consider Day One's intraday indicators
Day One intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Day One stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 32903.56 | |||
| Daily Balance Of Power | (0.70) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 13.5 | |||
| Day Typical Price | 13.45 | |||
| Price Action Indicator | (0.30) | |||
| Period Momentum Indicator | (0.28) | |||
| Relative Strength Index | 68.44 |
Day One Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 7th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Day Stock media impact
Far too much social signal, news, headlines, and media speculation about Day One that are available to investors today. That information is available publicly through Day media outlets and privately through word of mouth or via Day internal channels. However, regardless of the origin, that massive amount of Day data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Day One news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Day One relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Day One's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Day One alpha.
Day One Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Day One can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Day One Corporate Management
| PharmD Chiodin | Chief Officer | Profile | |
| Jaa Roberson | Chief Officer | Profile | |
| Elly MD | Chief Officer | Profile | |
| Adam Dubow | General Counsel | Profile | |
| Lauren MBA | Chief Officer | Profile | |
| Adam JD | General Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.144 | Return On Assets (0.25) | Return On Equity (0.18) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Day One's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.